Diabetes Schwerpunktpraxis
- Address
- Poststraße 48-50, 14612 Falkensee, Germany
Diabetes Schwerpunktpraxis - Cardiometabolic and Renal Research Center
Diabetes Schwerpunktpraxis is a specialized medical practice dedicated to advancing research in metabolic disorders and their complications. The center focuses on innovative therapeutic approaches for patients with complex cardiometabolic conditions, particularly investigating novel treatment combinations to improve patient outcomes and slow disease progression.
- Chronic kidney disease (CKD) progression and renal protection strategies
- Hypertension management in patients with metabolic complications
- Combination therapies targeting cardiorenal metabolic syndrome
The practice participates in cutting-edge clinical trials evaluating emerging pharmaceutical interventions, including studies examining the efficacy of baxdrostat combined with dapagliflozin versus standard treatments. Research efforts emphasize preserving renal function through measurement of estimated glomerular filtration rate (eGFR) changes over time, contributing valuable data to the understanding of how innovative drug combinations can benefit patients with concurrent chronic kidney disease and hypertension.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Diabetes Schwerpunktpraxis
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Comparative Efficacy of Inclisiran Sodium Versus Bempedoic Acid in LDL-C Reduction in Atherosclerotic Cardiovascular Disease Patients | Novartis Pharma GmbH | Phase III | Not Recruiting | Jun 2024 | Jan 2026 |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Atorvastatin | 1 | Unknown | 2024-06-21 | 2024-06-21 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.